Pharmacy Regulations 2010

The regulations instantiate a small set of core regulatory concepts: registration as a premises‑based authorisation, minimum competency and safety fit‑out standards, transparency about ownership and control, ongoing recordkeeping and confidentiality, and administrative pre‑approval for structural changes. Each concept is expressed through specific documentary or physical requirements and monetary penalties for non‑compliance.

Registration as a premises authorisation: Applications must include plans and specifications demonstrating compliance with Schedule 1 minimum standards (r 4(a)), plus an array of ownership and contractual documents (r 4(d)-(e)). Registration duration is pegged to the financial year, ending 30 June following registration, with yearly renewals thereafter (r 5). Replacement certificates and certified copies of the register are available for prescribed fees (r 7, r 10, Sch 2).

Minimum fitness and premises standards: Schedule 1 is the catalogue of minimum standards of fitness for competent and safe practice (r 13(1), Sch 1). It covers public access (Sch 1 cl 1), security measures against theft and unexplained loss (Sch 1 cl 2(2)), a specific equipment list with technical specifications (Sch 1 cl 3 and Table), minimum dispensary size and services (Sch 1 cl 6), access to named clinical and regulatory reference works (Sch 1 cl 4), and a private consultation area (Sch 1 cl 7).

Ownership transparency and register obligations: The register must include the name and business address of each person who owns or holds a proprietary interest in the pharmacy business, the nature of those interests, and the name and business address of the pharmacist with overall responsibility (r 8). When register information changes, the registered holder must notify the Board in writing within 14 days, on pain of a $500 penalty and payment of the $55 fee for updating the register (r 9, Sch 2).

Control of physical change and Board oversight: Significant alterations , defined to include changes to construction, structure, layout or floor area (r 11) , require prior written approval from the Board. Applications must be submitted at least two months before commencement, accompanied by plans, specifications and the $750 fee, and the Board may request further information to decide (r 14(1)-(4), Sch 2). The Board’s power to withhold approval is limited by a statutory standard: it must be satisfied that proposed alterations would cause the pharmacy to cease meeting the Schedule 1 minimum standards (r 14(5)).

Clinical and commercial constraints: The regulations expressly prohibit the sale or supply of tobacco products at registered pharmacies (r 12). Recordkeeping and confidentiality obligations apply to all prescriptions dispensed, with retention at the pharmacy for 24 months (r 16). The regulations also require premises to be well lit, ventilated and air conditioned and to keep fixtures in good repair (r 15).

Fees and penalties: Schedule 2 fixes a set of fees for applications and administrative services (registration $1,150; renewal $950; significant alteration $750; various $55 fees) and the regulations set fines for specified offences (for example, selling tobacco $5,000; failure to notify register changes $500; breaches concerning significant alterations, premises maintenance and recordkeeping $1,000,see rr 9, 12, 14, 15, 16 and Sch 2).

Transitional and cross‑referencing features: Regulation 13(2) provides transitional relief for pharmacies registered under the old Act by postponing certain Schedule 1 requirements until after the next significant alteration. Regulation 3 prescribes certain permit and licence types from the Medicines and Poisons Regulations 2016 for purposes of the Act’s definition of “pharmacy business”, thereby aligning regulatory definitions across instruments.

The regulations directly affect registered pharmacies (the premises), persons and entities holding proprietary interests in pharmacy businesses, and the pharmacist with overall responsibility for a pharmacy. They also implicate applicants seeking registration, architects and fit‑out contractors (because plans and certifications are required), and the Pharmacy Board as regulator.

Owners and proprietary interest holders: The application and register rules impose documentary disclosure obligations on owners and persons with proprietary interests. An initial application must include detailed information about each person who owns or holds a proprietary interest in the pharmacy business, including the nature of the interest, name and address, and a telephone and email contact (r 4(d)(i)-(iii)). The application must also include copies of bills of sale, sale agreements, partnership agreements, leases, trust deeds where a pharmacist controlled company is trustee, security interests, and management or service contracts (r 4(e)(i)-(x)). The register must also include proprietary interest details for each registered pharmacy (r 8). These provisions directly affect shareholding structures, trust arrangements, partnerships, franchisors and management companies involved in pharmacy operations.

Pharmacists with overall responsibility: The regulations place primary operational obligations on the pharmacist with overall responsibility. That person must not permit significant alterations without the Board’s prior written approval (r 14(1)), must apply at least two months before commencement of alterations (r 14(2)), must ensure the premises are well lit, ventilated and kept clean and in good repair (r 15), and must ensure that records of all prescriptions dispensed are made, stored in a secure location at the pharmacy, confidentially handled and retained for 24 months (r 16(1)-(2)). These duties attach personally to the pharmacist with overall responsibility, not merely to corporate owners (definitions r 11).

Applicants and prospective registrants: Entities seeking to register premises as a pharmacy must submit plans and specifications demonstrating compliance with Schedule 1, provide extensive ownership and contractual documentation, and pay the $1,150 application fee (r 4, Sch 2). They must also design premises to meet the physical standards: dispensary area of at least 10 m², sink with hot and cold running water, a private consultation area, security devices, and specified equipment (Sch 1 cl 3, cl 6, cl 7).

Third parties and contractors: Architects, engineers and fit‑out contractors will need to produce plans that demonstrate compliance with Schedule 1 and the Board may request further information about proposed significant alterations (r 14(4)). Suppliers of equipment must meet particular technical specifications where indicated (for example, scales in Sch 1 cl 3 item 8).

Customers and the public: The prohibition on tobacco sales (r 12) affects customer choice and eliminates a commercial product line previously sold in some pharmacies. The requirement for an area where pharmacist consultations are not likely to be overheard (Sch 1 cl 7) directly affects the privacy of patients and the structure of counselling services.

The Board and enforcement agencies: The Board is the decision‑maker for registration and approvals, holds the register and may charge fees for certified copies and minutes (r 7, r 10, r 18, Sch 2). It also has limited discretion to request further information and to withhold approval for significant alterations only where the resulting premises would fail to meet the Schedule 1 standard (r 14(4)-(5)).

Persons ceasing to be close family members: Regulation 17 prescribes a handling pathway where someone ceases to be a close family member of a pharmacist by death, divorce or separation and holds a proprietary interest in a partnership or pharmacist controlled company: the person must divest the interest within a Board‑approved period, and if the change was due to divorce or separation the company or partnership must redeem the interest in accordance with constitutional or partnership rules (r 17).

Other regulatory instruments and agencies: The regulations affect how pharmacies interact with the Medicines and Poisons Act 2014 and its Regulations (Sch 1 cl 4, r 3) and with the Tobacco Products Control Act 2006 (definitions in r 11). This creates compliance obligations that straddle multiple statutory regimes.

Duties: The regulations allocate explicit duties primarily to the pharmacist with overall responsibility and to the person in whose name the pharmacy is registered.

• Duty to supply information and documents at application: An application for registration must be accompanied by sufficiently detailed plans and specifications showing compliance with Schedule 1, and a comprehensive suite of ownership and contractual documents (r 4(a), (d), (e)). Failure to lodge a compliant application will prevent registration.

• Duty to keep register information current: The person named on the register must notify the Board in writing within 14 days of any change to the information recorded in the register; failure attracts a $500 fine (r 9). There is also a $55 fee for lodging the change (r 9(2), Sch 2).

• Duty to seek Board approval for significant alterations: The pharmacist with overall responsibility must not cause or permit significant alterations without prior written Board approval, must apply at least two months before commencement, submit plans and the $750 fee, and respond to Board requests for further information (r 14(1)-(4), Sch 2).

• Duty to maintain premises and fixtures: The pharmacist with overall responsibility must ensure the pharmacy is well lit, adequately ventilated, air conditioned and properly maintained, clean and hygienic (r 15). Breach attracts a $1,000 fine.

• Duty to record and retain prescriptions: The pharmacist with overall responsibility must ensure that a record is made of all prescriptions dispensed at or from the pharmacy, that records are kept at the pharmacy in a safe and secure location, dealt with confidentially, and retained for 24 months after dispensing (r 16(1)-(2)). Penalties for breach are $1,000 for each subregulation breach.

• Duty to comply with minimum standards: The minimum standards in Schedule 1 are prescribed as the required standards of fitness for competent and safe practice (r 13(1)). For pharmacies registered under the old Act that do not meet specific items (Sch 1 item 6(1) or item 7), those particular requirements only apply after the next significant alteration (r 13(2)).

• Duty to divest or to have interests redeemed when family ties cease: A person who ceases to be a close family member of a pharmacist due to death, divorce or separation and who holds a proprietary interest in a partnership or pharmacist controlled company must divest the interest within the Board‑approved period, or have the interest redeemed by the company or partnership where divorce or separation caused the change (r 17).

Rights and delegations:

• Right to apply and receive registration: Applicants who meet the documentary, physical and fee requirements have the right to registration; the Board processes and issues certificates and replacement certificates on payment of fees (r 4, r 7, Sch 2).

• Right to request certified copies and minutes: Parties may obtain certified copies of the register or an entry, and copies of Board minutes available for inspection on payment of specified fees ($55 each) (r 10, r 18, Sch 2).

• Board discretion with limits: The Board may request further information to decide an application (r 14(4)). The Board’s power to withhold approval of significant alterations is circumscribed: it must not withhold unless it is satisfied that the alterations, if carried out as provided, would cause the pharmacy to cease to meet Schedule 1 minimum standards (r 14(5)). That is a legal constraint on Board discretion recorded in the regulations.

• Transitional relief for old registrations: Pharmacies taken to be registered under the old Act are not immediately compelled to meet certain Schedule 1 items until they carry out significant alterations (r 13(2)). That creates a time‑limited compliance pathway.

Financial rights and obligations:

• Applicants and registrants have the right to administrative services (certificates, register copies) but are obliged to pay the Schedule 2 fees: initial registration $1,150, renewal $950, application for significant alteration $750, and various $55 fees for replacements and certified copies (Sch 2).

Enforcement and penalties are administrative and monetary rather than automatically criminally severe. The regulations typically impose fines (for example $1,000 for breaches of r 14, r 15, r 16; $5,000 for selling tobacco at a pharmacy) rather than imprisonment. Those fines attach to the person responsible under the regulations (often stated as the pharmacist with overall responsibility or the person in whose name the pharmacy is registered).

Interaction with other obligations: Regulation 16(3) makes clear that the recordkeeping duties are “in addition to and not in derogation of any other law relating to the duty of a person to make and keep records”, signalling that obligations under privacy, health records or medicines and poisons legislation remain applicable.

Penalties under the regulations are primarily monetary fines attached to specific contraventions and in some places fees for administrative services. Enforcement responsibility rests with the Pharmacy Board and, more generally, with the compliance framework established by the Pharmacy Act 2010, to which these regulations are subordinate.

Specified fines and their triggers:

• Sale or supply of tobacco products at a registered pharmacy is prohibited and attract a fine of $5,000 (r 12). This is the highest single monetary penalty in the regulations.

• Failure by the person in whose name the pharmacy is registered to notify the Board of changes to information recorded in the register within 14 days attracts a $500 fine (r 9(1)). The same activity requires payment of a $55 fee for the change (r 9(2), Sch 2).

• Significant alterations: A pharmacist with overall responsibility must not cause or permit significant alterations without prior written approval. Contravention carries a fine of $1,000 (r 14(1)). Failure to apply at least two months before commencement carries a fine of $500 (r 14(2)). Applications must be accompanied by plans and the $750 fee (r 14(3), Sch 2). The Board may request further information before deciding (r 14(4)).

• Premises maintenance: The pharmacist with overall responsibility must ensure the pharmacy is well lit, ventilated and air conditioned, and that fixtures are maintained in safe, clean, hygienic condition and good repair. Breach carries a fine of $1,000 (r 15).

• Recordkeeping: The pharmacist with overall responsibility must ensure a record of all prescriptions dispensed is made (r 16(1)), that such records are kept at the pharmacy in a safe, secure and confidential manner (r 16(2)(a)), and that records are retained at the pharmacy for 24 months (r 16(2)(b)). Each subregulation breach carries a fine of $1,000.

Administrative fees targeted to service functions:

• Schedule 2 sets fees for administrative services and applications: registration application $1,150 (r 4), renewal $950 (r 6), significant alteration application $750 (r 14), replacement certificate $55 (r 7), change to register $55 (r 9), certified copy of the register $55 (r 10), and copy of Board minutes $55 (r 18, Sch 2).

Board enforcement levers and limits:

• The Board may request further information and must be satisfied as to compliance when considering applications for significant alteration (r 14(4)-(5)). The Board’s refusal power is limited to circumstances where alterations, if carried out as proposed, would result in non‑compliance with Schedule 1; it cannot withhold approval on other grounds set out in the regulations (r 14(5)).

• Replacement certificates and certified copies may be issued for the specified fees (r 7, r 10). The Board retains the register and the power to require registration particulars (r 8).

Interaction with other enforcement regimes:

• Recordkeeping obligations are expressly stated to be additional to other laws relating to making and keeping records (r 16(3)), linking regulatory compliance to other statutory regimes, including privacy and medicines/poisons regulation frameworks.

Practical enforcement considerations and implementation risk:

• Monetary fines are modest relative to large corporate turnovers but non‑trivial for small community pharmacies. The larger penalty for tobacco sale ($5,000) is designed to remove a specific revenue stream and to enforce a public‑health decision in premises that are registered pharmacies (r 12).

• Board discretion to request additional information (r 14(4)) and to decide whether alterations would cause non‑compliance (r 14(5)) introduces an administrative timeline and uncertainty for applicants. The statutory requirement to apply at least two months before the commencement of significant alterations (r 14(2)) creates a minimum planning horizon; the Board’s ability to request further information may extend that horizon.

• Fines attached to recordkeeping and maintenance duties create incentives for routine compliance checks; the regulation that records be kept “at the pharmacy” in a “safe and secure location” (r 16(2)(a)) may raise questions about whether off‑site electronic storage satisfies the obligation , the text is locative and may be interpreted to require on‑site physical or controlled local electronic access. Enforcement practice will determine how strictly “at the pharmacy” is interpreted.

These regulations are designed to operate as subordinate legislation to the Pharmacy Act 2010 and are expressly cross‑referential with other Acts and regulations. Several provisions either derive their meaning from other statutes or require compliance with external regulatory instruments.

Integration with the Pharmacy Act 2010: The regulations implement statutory functions and standards required by the Act. Multiple regulations are expressly for the purposes of named sections of the Act: e.g. regulation 3 for s 3(1) definitions (pharmacy business), regulation 4 for applications under s 42, regulation 5 for duration under s 45, regulation 8 for register information under s 49(2)(d), and regulation 10 for certified copies under s 50(4). Regulation 13 prescribes Schedule 1 as the minimum standards for the purposes of the Act (r 13(1)). The Board’s powers and obligations under the Act (including decisions about registration and enforcement) are implemented through these regulations.

Cross reference to Medicines and Poisons Act and Regulations: The regulations incorporate permit and licence types from the Medicines and Poisons Regulations 2016 into the Act’s notion of “pharmacy business” (r 3). Specifically, r 3(a) prescribes certain permit types listed in the Medicines and Poisons Regulations 2016 regulation 79(2) (Health service permit, Government permit, Research/Education permit, et cetera) and r 3(b) prescribes a type of licence that is a Schedule 2 retail licence referred to in regulation 74(2) of the Medicines and Poisons Regulations 2016. Schedule 1 cl 4 requires access to the Medicines and Poisons Act 2014 and the Medicines and Poisons Regulations 2016. This alignment means that pharmacy regulatory compliance must be read alongside the medicines and poisons framework.

Definitions and other Acts: The regulations import definitions or meaning from other statutes. The term “prescription” is given the meaning in the Medicines and Poisons Act 2014 s 3 (r 11). The term “tobacco product” is defined by reference to the Tobacco Products Control Act 2006 Glossary (r 11) and the prohibition on tobacco sales at pharmacies (r 12) rests on that definition.

Privacy and records law: Regulation 16(2)(a) requires records to be kept “in a safe and secure location and dealt with in a confidential manner”, and regulation 16(3) expressly states that the regulation is in addition to and not in derogation of any other law relating to making and keeping records. This preserves any obligations under the Privacy Act 1988 (Commonwealth) or any state privacy, health records or mandatory reporting laws. Practitioners should read r 16 in tandem with applicable privacy and health records legislation to determine retention, consent, access, and disclosure obligations.

Tobacco regulation and public‑health law: Regulation 12’s explicit prohibition on the sale or supply of tobacco products at registered pharmacies gives effect to a policy line that intersects with the Tobacco Products Control Act 2006. The regulatory interplay is direct: the definition of “tobacco product” comes from the Tobacco Products Control Act and r 12 creates an additional restriction on pharmacies.

Property and corporate law: The requirement to supply copies of bills of sale, sale agreements, partnership agreements, lease agreements, trust deeds and security interests (r 4(e)(i)-(x)) implicates property law and corporate governance. Where a pharmacist controlled company acts as trustee, applicants are to provide the trust deed (r 4(e)(ix)). Regulation 17 prescribes how proprietary interests held by persons who cease to be close family members are to be divested or redeemed, creating an interaction with corporate constitutions and partnership rules; these provisions require compliance with company constitutions or partnership rules and with trust instruments where applicable.

Local government and building standards: Schedule 1 sets physical premises standards (e.g. dispensary area, plumbing, ventilation, public access) that will interact with building approvals, planning and local government requirements. Registered premises must have at least one door allowing direct access from a street or thoroughfare and have no direct access to adjoining premises (Sch 1 cl 1). Design and fit‑out will therefore need to satisfy both the Board’s expectations and local building regulations.

Transitional and prior law: Regulation 13(2) provides transitional relief for pharmacies registered under the old Act, postponing compliance with Sch 1 item 6(1) (dispensary area) or item 7 (private consultation area) until after next significant alterations. For any pharmacy that existed before the Pharmacy Act 2010 s 3 came into operation, compliance timelines will be governed by this transitional provision.

Administrative law and procedural fairness: The Board’s ability to request further information (r 14(4)) and to refuse approval only where alterations would cause failure to meet Schedule 1 (r 14(5)) implies a constrained discretionary decision‑making framework. Applicants may have administrative law remedies under the Act or general administrative law principles if they consider the Board has acted beyond the statutory limits, but those remedies and their availability are matters outside the text of these regulations.

The regulations include a compilation table showing amendments and their commencement dates, and the body text contains specific insertions and changes made at various times. The compilation table lists the original Pharmacy Regulations 2010 (published 1 Oct 2010; regs other than 1 and 2 commenced 18 Oct 2010) and several amending instruments. Key amendment entries in the table and in the text are as follows.

• Pharmacy Amendment Regulations 2012 (published 1 Jun 2012, most provisions from 1 Jul 2012). The compilation table records this amending instrument. Specific changes effected by the 2012 instrument are not detailed in the text provided.

• Health Regulations Amendment (Poisons) Regulations 2016 Pt. 4 (published 17 Jan 2017, commenced 30 Jan 2017). The body of these regulations records that r 3 was inserted and that r 11 and Sch 1 cl 4 were amended (see annotations in r 3 and notes in Sch 1 cl 4). Specifically, regulation 3,prescribing certain permit types under the Medicines and Poisons Regulations 2016 for the purposes of the Pharmacy Act 2010 s 3(1) definition of pharmacy business,was inserted by Gazette 17 Jan 2017 p. 411. Regulation 11 was also amended on 17 Jan 2017 (annotation r 11 amended: Gazette 17 Jan 2017 p. 411). Clause 4 in Schedule 1 (access to reference documents) was amended and bears the same annotation.

• Pharmacy Amendment Regulations 2019 (published 24 Dec 2019, most provisions from 25 Dec 2019). The compilation table includes this instrument but the text does not annotate which specific provisions changed in 2019.

• Pharmacy Amendment Regulations 2024 (SL 2024/110, published 26 Jun 2024, most provisions commenced 1 Jul 2024). The Schedule 2 fee table shows the heading insertion note and the schedule insertion note [Schedule 2 inserted: SL 2024/110 r. 4], indicating the fees table was inserted or substantially revised in 2024. The notes in Schedule 2 itself record SL 2024/110 r. 4 as the insertion instrument.

Textual annotations within the regulations identify particular insertions or amendments: r 3 includes an insertion annotation indicating it was added in Jan 2017; r 11 includes an amendment note pointing to 17 Jan 2017; Sch 1 cl 4 is annotated as amended 17 Jan 2017; Schedule 2 is annotated as inserted in 2024. The compilation table at the end provides the official dates of publication and commencement for each amending instrument.

Practical effects of amendments visible in the text:

• The 2017 amendments (Health Regulations Amendment (Poisons) Regulations 2016 Pt. 4) aligned the definition of “pharmacy business” with particular permit and licence types in the Medicines and Poisons Regulations 2016 (r 3). They also clarified Schedule 1’s required access to the Medicines and Poisons Act 2014 and its regulations (Sch 1 cl 4 amendment).

• The 2024 amendment inserted Schedule 2, formalising fees for registration, renewal, significant alteration and various administrative services (Sch 2 inserted SL 2024/110 r. 4). Schedule 2 lists specific monetary amounts (for example registration $1,150, renewal $950).

• Other amendments in 2012 and 2019 are referenced in the compilation table; the exact textual changes from those instruments are not specified in the excerpt provided.

For compliance and advisory purposes, the compilation table and the in‑text annotations are the primary source for tracking when a particular regulatory requirement took effect and under which amending instrument it was introduced or altered (see the “Compilation table” at the end of the document).

The regulations themselves do not record any cases or litigation history. The instrument contains no citations to judicial decisions, and the compilation table lists only amending statutory instruments. Therefore, there is no litigation history contained within this text to summarise or cite.

Practically, matters that could give rise to litigation or administrative review under these regulations would include disputes over the Board’s exercise of its approval or refusal powers for significant alterations (r 14(4)-(5)), disputes about register entries or the Board’s interpretation of proprietary interests disclosed on application (r 4, r 8), and enforcement challenges to fines or penalties imposed for breach of provisions such as the prohibition on tobacco sales (r 12), or recordkeeping obligations (r 16). Any such cases, if commenced, would appear in external case law reporters or judicial databases; they are not contained in the regulation text and therefore not included here.

If a practitioner requires an authoritative history of litigation interacting with these regulations, the next step is to search administrative law and Western Australian court databases for cases citing the Pharmacy Act 2010 and the Pharmacy Regulations 2010, or to check Board decisions and published reasons, none of which are supplied in the regulation text itself.

The regulations contain several specific drafting features and obligations that present practical traps for practitioners and pharmacy operators. These “gotchas” are concrete obligations or traps for the unwary, grounded in the text.

Notification timing and penalty: A registered holder must notify the Board in writing within 14 days of any change to information recorded in the register (r 9(1)). The penalty is $500, and a $55 fee is payable when giving notice (r 9(2), Sch 2). The short 14‑day window is a compliance risk for transactions or restructures that change ownership or contact details, and the $500 fine applies irrespective of the commercial scale of the change.

Extensive documentary burden at application: An initial application for registration must include not only plans and specifications but also an extensive set of ownership and contractual documents (r 4(e)(i)-(x)). The list includes bills of sale, sale agreements, partnership agreements, leases, proprietary interest agreements, management service agreements, support services contracts, trust deeds where a pharmacist controlled company is trustee, and any security interests. Missing or incomplete documentation risks rejection or requests for further information and delay.

Location of records: Regulation 16(2)(a) requires that prescription records be “kept at the pharmacy in a safe and secure location”. This wording may create uncertainty for models that rely on centralised off‑site servers or cloud storage where records are physically stored elsewhere. The regulation does not define whether “kept at the pharmacy” is satisfied by secure, immediately accessible electronic access to off‑site storage. Until clarified by the Board or case law, there is a compliance risk for those using remote archiving solutions.

Short minimum retention period: Records must be retained at the pharmacy for 24 months after dispensing (r 16(2)(b)). That is shorter than some medical record retention standards for other health services. Because r 16(3) states the obligations are “in addition to” other laws, obligations under other statutes or contractual arrangements may require longer retention periods; operators must reconcile competing retention rules.

Definition and consequences of “significant alteration”: Significant alteration is broadly defined to include changes affecting construction, structure, layout or floor area (r 11). The definition can capture both major refits and some relatively modest layout changes. The pharmacist with overall responsibility must apply at least two months before commencement and pay the $750 fee (r 14(2)-(3)). Carrying out an alteration without prior approval attracts a $1,000 fine (r 14(1)). Operators who proceed with fit‑outs without Board approval risk enforcement and may be required to remediate.

Transitional relief is narrow: If a pharmacy registered under the old Act does not meet certain Schedule 1 items, the requirement only applies after the next significant alteration (r 13(2)), covering Sch 1 item 6(1) (dispensary area) and item 7 (private consultation area). That relief is narrow and limited to those items, meaning other Schedule 1 requirements apply immediately.

Equipment specificity: Schedule 1 prescribes particular equipment with technical specifications (Sch 1 cl 3 and Table), for example scales with specified readability (Sch 1 cl 3 item 8). Satisfying those specifications may require capital expenditure on equipment meeting technical tolerances. Failure to install the required equipment could impede registration or provoke compliance action.

Prohibition of tobacco sales: The absolute prohibition on selling or supplying tobacco products at a registered pharmacy (r 12) may remove a recurring commercial revenue line. Any stock on hand must be segregated and removed; failure to comply exposes operators to a $5,000 fine. That monetary penalty is substantial relative to other penalties in the regulations and operates as a strict bar.

Public access and shopfront requirements: Schedule 1 clause 1 requires at least one door allowing direct access to members of the public from a street or thoroughfare and no direct access to adjoining premises. This may affect premises situated within shopping malls, arcades, or multi‑unit buildings where direct external access is limited or where access is shared. Such locations may not qualify or may require restructuring to comply.

Board requests for further information and approval timing: The Board may request further information to decide an application for significant alteration (r 14(4)). Although the regulations require application at least two months before commencement (r 14(2)), the Board’s request may extend decision timelines and delay projects. There is no statutory deadline by which the Board must decide; the only statutory constraint is the standard for withholding approval (r 14(5)). Practitioners should plan for possible extensions.

Trustee structures and family changes: Regulation 4(e)(ix) requires trust deeds where a pharmacist controlled company is acting as trustee. Regulation 17 imposes divestment or redemption obligations where a person ceases to be a close family member by death, divorce or separation. Those provisions interact with family law and trust law and can produce forced divestments or redemptions that must be managed under company constitutions or partnership rules.

Fees and timing aligning with the financial year: Registration takes effect until 30 June following registration (r 5(1)), and renewals follow 12‑month cycles (r 5(2)). Applicants who register mid‑year may face a truncated first registration period and must plan cashflow for the next renewal.

Compliance requires a combination of forward planning for premises and capital expenditure, disciplined corporate disclosure, and operational systems for recordkeeping and maintenance. The following practical steps follow directly from the regulations’ requirements.

1. Pre‑application due diligence and documentation (r 4).

   • Compile plans and specifications that show the premises meet Schedule 1 minimum standards, including dispensary layout of at least 10 m², sink with hot and cold running water, private consultation area, and required equipment specs (Sch 1 cl 3, cl 6, cl 7).
   • Assemble ownership and proprietary documentation: bills of sale, sale agreements, partnership agreements, leases, agreements conferring proprietary interests, management services or support services contracts, trust deeds where a pharmacist controlled company is trustee, and any security interests (r 4(e)(i)-(x)).
   • Ensure contact details for each person who owns or holds a proprietary interest (nature of interest, name, address, telephone and email) are ready for the application (r 4(d)(i)-(iii)).
   • Budget for the initial registration fee of $1,150 (Sch 2).

2. Fit‑out and equipment compliance (Sch 1).

   • Ensure the dispensary meets the minimum 10 m² area and has an appropriate sink and utilities (Sch 1 cl 6(1)-(2)).
   • Provide the specified equipment, including bar code scanner(s) at each dispensing station, balances meeting the stated precision/readability, and other items listed in Sch 1 cl 3 Table.
   • Install security devices and systems to reduce risk of burglary, robbery, theft and unexplained loss (Sch 1 cl 2(2)).
   • Provide a private consultation area designed to prevent reasonable likelihood of being overheard (Sch 1 cl 7).
   • Confirm public access requirements (a direct door from a street or thoroughfare and no direct access to adjoining premises) are met (Sch 1 cl 1).

3. Access to reference materials (Sch 1 cl 4).

   • Ensure immediate access (hard copy or electronic) to the latest editions and supplements of: Australian Medicines Handbook (AMH), Australian Pharmaceutical Formulary and Handbook, MIMS annual or eMIMS or AusDI, Therapeutic Guidelines (complete series), the Pharmacy Act 2010 and Pharmacy Regulations 2010, and the Medicines and Poisons Act 2014 and Medicines and Poisons Regulations 2016.

4. Apply for registration and anticipate timelines (r 4, r 5).

   • Lodge the application in the approved form, attach the plans and documentary requirements, and pay the $1,150 fee (r 4, Sch 2).
   • Note that initial registration runs to the next 30 June; budget for renewal fees ($950) accordingly (r 5, r 6, Sch 2).

5. Managing significant alterations (r 14).

   • If planning construction, layout changes, or alterations impacting floor area, prepare a significant alteration application at least two months before works commence and include plans, specifications and the $750 fee (r 14(2)-(3), Sch 2).
   • Account for the Board’s potential request for further information and the lack of a guaranteed statutory decision period; schedule projects with buffer time (r 14(4)).
   • Do not commence significant alterations until you have written Board approval; contravention attracts a $1,000 fine (r 14(1)).

6. Operational obligations and recordkeeping (r 15, r 16).

   • Implement maintenance schedules to ensure adequate lighting, ventilation, air conditioning and hygienic fixtures (r 15). Document inspections and remedial works to demonstrate compliance if inspected.
   • Put in place systems to record every dispensed prescription and to retain records for 24 months at the pharmacy in a safe, secure location, and ensure confidential handling (r 16(1)-(2)). If using electronic record systems, ensure immediate local accessibility and that an on‑site secure copy or controlled access is available if required. Reconcile this with other legal retention obligations under privacy and health records laws (r 16(3)).

7. Register maintenance and disclosure (r 8, r 9).

   • Ensure the register contains required details of proprietary interests and the pharmacist with overall responsibility. Maintain accurate contact details and notify the Board within 14 days of changes, paying the $55 updating fee (r 8, r 9(1)-(2), Sch 2).
   • Designate an internal compliance owner responsible for monitoring and lodging register changes within the 14‑day window to avoid the $500 penalty (r 9(1)).

8. Corporate and family‑law events planning (r 17).

   • For proprietary interests held by persons who may cease to be close family members (death, divorce, separation), prepare contractual mechanisms and company/partnership constitutional rules to allow for redeeming or divesting interests within Board approved periods. Review trust deeds if pharmacist controlled companies act as trustees (r 4(e)(ix), r 17).

9. Tobacco stock and product policies (r 12).

   • Remove tobacco product lines from the pharmacy’s inventory and point‑of‑sale systems, and train staff to refuse tobacco sales. The penalty for non‑compliance is $5,000 (r 12).

10. Administrative services and fees (r 7, r 10, r 18, Sch 2).

    • Keep budgets for replacement certificates ($55), certified copies of the register ($55) and Board minutes ($55). Use the Board’s online or prescribed forms for obtaining such documents (r 7, r 10, r 18, Sch 2).

11. Record processes and audits.

    • Maintain an audit trail for plans, approvals, maintenance records, training, equipment purchases and disposal of tobacco stock. Regular internal audits reduce the risk of fines for maintenance, recordkeeping or procedural failings (rr 15-16).

12. Liaise with the Board and parallel regulators.

    • Where uncertainty exists (for example, whether a specific layout change is a “significant alteration” or whether off‑site electronic storage counts as “kept at the pharmacy”), seek the Board’s guidance in writing before acting. Keep contemporaneous correspondence to show proactive compliance steps (r 14(4)).

These compliance steps map directly to the regulation text and fees schedule. Where external legal obligations intersect (privacy laws, medicines and poisons controls, building approvals, company and trust law), coordinate compliance across those instruments to avoid contradictory practices.